Error in Table
In the original article, there was a mistake in Table 1 as published. The author identified the calculating errors in the percentage of comorbidity, symptoms, and treatment. The corrected Table 1 appears below.
Table 1.
Clinical and relevant baseline characteristics of patients.
| Characteristic | Total (n = 115) | IVIg group (n = 26) | Control group (n = 89) | SD (%) |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR) | 59 (47–69) | 58 (42–65) | 59 (48–70) | 16 |
| Male sex, No. (%) | 76 (66) | 19 (73) | 57 (64) | 18 |
| Any comorbidity, No. (%) | ||||
| Hypertension | 52 (45) | 10 (38) | 42 (47) | 9 |
| Diabetes | 24 (21) | 2 (8) | 22 (25) | 39 |
| Chronic cardiac disease | 18 (16) | 5 (19) | 13 (15) | 11 |
| Chronic respiratory disease | 11 (10) | 2 (8) | 9 (10) | 4 |
| Any symptoms, No. (%) | ||||
| Fever | 111 (97) | 22 (85) | 89 (100) | 31 |
| Cough | 97 (84) | 22 (85) | 75 (84) | 8 |
| Dyspnea | 96 (83) | 22 (85) | 74 (83) | 10 |
| Fatigue or myalgia | 52 (45) | 9 (35) | 43 (48) | 19 |
| Diarrhea | 30 (26) | 4 (15) | 26 (29) | 24 |
| Vital signs | ||||
| Systolic BP, mm Hg | 132 ± 19 | 131 ± 14 | 133 ± 20 | 5 |
| HR,/min | 88 (80–102) | 85 (81–100) | 89 (80–105) | 9 |
| RR, breaths/min | 22 (20–25) | 22 (20–23) | 22 (20–25) | 2 |
| SPO2, % | 90 (87–94) | 91 (89–94) | 89 (86–92) | 6 |
| Complete blood count | ||||
| WBCs, × 109/L | 6.59 (4.38–9.64) | 6.25 (4.15–10.28) | 6.60 (4.42–9.56) | 4 |
| LYM, × 109/L | 0.76 (0.57–1.02) | 0.90 (0.62–1.05) | 0.73 (0.56–0.91) | 19 |
| PLT, × 109/L | 191 (148–269) | 172 (144–279) | 199 (150–270) | 18 |
| Inflammatory biomarkers | ||||
| IL–6, pg/mL | 13.0 (8.0–31.5) | 15.5 (10.5–34.0) | 11.0 (7.2–32.2) | 15 |
| IL–8, pg/mL | 15.2 (6.0–27.3) | 16.2 (5.8–23.8) | 15.2 (5.9–28.4) | 3 |
| IL–10, pg/mL | 5.2 (5.0–10.3) | 5.0 (5.0–8.5) | 5.5 (5.0–11.2) | 2 |
| hsCRP, mg/L | 48 (17–94) | 28 (7–91) | 45 (17–101) | 14 |
| Ferritin, ng/mL | 807.0 (473.4–1383.3) | 774.1 (444.2–1525.4) | 838.8 (501.5–1351.1) | 18 |
| ESR, mm/h | 50 (25–65) | 35 (19–67) | 50 (27–65) | 14 |
| Immunoglobulins | ||||
| IgA, g/L | 2.2 (1.8–3.0) | 2.7 (1.9–4.6) | 2.2 (1.6–3.0) | 2 |
| IgG, g/L | 11.1 (9.0–13.1) | 11.8 (8.5–15.7) | 11.1 (9.3–13.1) | 2 |
| IgM g/L | 1.0 (0.7–1.2) | 1.0 (0.9–1.1) | 0.9 (0.7–1.3) | 3 |
| Seven–category scales at admission | 4.0 ± 0.67 | 3.85 ± 0.67 | 4.06 ± 0.66 | 26 |
| 3, No. (%) | 20 (17) | 7 (27) | 13 (15) | 24 |
| 4, No. (%) | 79 (69) | 17(65) | 62 (70) | 7 |
| 5, No. (%) | 11 (10) | 1 (4) | 10 (11) | 25 |
| 6, No. (%) | 5 (4) | 1 (4) | 4 (4) | 3 |
| Murray lung injury scores at admission | 3.93 ± 0.22 | 3.90 ± 0.28 | 3.94 ± 0.20 | 11 |
| Time to admission after onset, median (IQR) | 10 (7–12) | 10 (7–12) | 10 (8–12) | 5 |
| Earlier (< 7 days), No. (%) | 29 (25) | 7 (27) | 22 (25) | 12 |
| Later (between 7–14 days), No. (%) | 86 (75) | 19 (73) | 67 (75) | 12 |
| Treatment during hospitalization, No. (%) | ||||
| Antiviral treatment | 100 (87) | 22 (85) | 78 (88) | 7 |
| Arbidol | 75 (65) | 15 (58) | 60 (67) | 16 |
| IFN–α | 34 (30) | 14 (54) | 20 (22) | 53 |
| LPV/r | 31 (27) | 9 (35) | 22 (25) | 17 |
| RBV | 12 (10) | 3 (12) | 9 (10) | 4 |
| OSV | 33 (29) | 8 (31) | 25 (28) | 5 |
| Antibiotic treatment | 100 (87) | 25 (96) | 75 (84) | 37 |
| Moxifloxacin | 73 (63) | 15 (58) | 58 (65) | 12 |
| Cefoperazone and tazobactam | 47 (41) | 13 (50) | 34 (38) | 19 |
| Antifungal treatment | 11 (10) | 5 (19) | 6 (7) | 29 |
| TCM | 58 (50) | 15 (58) | 43 (48) | 15 |
| LMWH | 19 (16) | 4 (15) | 15 (17) | 3 |
| Glucocorticoids | 71 (62) | 18 (69) | 53 (60) | 17 |
| IVIg therapy | 26 (23) | 26 (100) | 0 (0) | — |
| Initiation time, days, median (IQR) | — | 2 (1–4) | — | — |
| Course, days, median (IQR) | — | 5 (5–9) | — | — |
| Amount, g, median (IQR) | — | 122.5 (95.0–213.8) | — | |
SD, standard deviation; Tmax, maximal temperature; BP, blood pressure; HR, heart rate; RR, respiratory rate; SPO2, pulse oximeter O2 saturation; WBC, white cell counts; LYM, lymphocyte counts; PLT, platelet counts; IL, interleukin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IFN-α, Interferon-alfa; LPV/r, lopinavir/ritonavir; RBV, ribavirin; OSV, oseltamivir; TCM, traditional Chinese medicine; LMWH, low molecular weight heparin.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.